Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: A therapeutic challenge

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 12, 2007, Pages 1154-1159

  Papadogias, Dimitrios ^a   Makras, Polyzois ^b   Kossivakis, Kostantinos ^c   Kontogeorgos, George ^c   Piaditis, George ^c   Kaltsas, Gregory ^d  

^a IASO   (Greece)

^b Hellenic Air Force Hospital   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carcinoid crisis; Carcinoids; Neuroendocrine tumours; Oncology

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; CETIRIZINE; CISPLATIN; ETOPOSIDE; HYDROCORTISONE; INDIUM 111; LOPERAMIDE; OCTREOTIDE; RANITIDINE;

ADULT; AGGRESSION; ARTICLE; BONE METASTASIS; BRONCHUS CARCINOID; CANCER GROWTH; CARCINOID SYNDROME; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; HYPOKALEMIA; LUNG INJURY; LUNG SCINTISCANNING; MALE; PARALYTIC ILEUS; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR CLASSIFICATION;

CARCINOID TUMOR; FATAL OUTCOME; HUMANS; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED;

EID: 36248989726     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282294d88     Document Type: Article

References (38)

1. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002; 14:38-45.
2. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352:799-805.
3. Kaltsas G, Besser GB, Grossman A. The diagnosis and medical management of advanced neuroendocrine tumors.Endocr Rev 2004; 25:458-511.
4. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119:1647-1651.
5. Laitinen KL, Soini Y, Mattila J, Paakko P. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer 2000; 88:1590-1598.
6. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al.; Nordic NE Tumour Group. Guidelines for the management of gastroentero-pancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II - specific NE tumour types. Acta Oncol 2004; 43:626-636.
7. Bishop AE, Polak JM. Gastrointestinal endocrine tumours. Pathology. Baillieres Clin Gastroenterol 1996; 10:555-569.
8. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2):S47-S50.
9. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79:1086-1093.
10. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001; 12 (Suppl 2):S95-S99.
11. Kvols LK, Martin JK, Mash HM, Moertel CG Rapid reversal of carcinoid crisis with a somatostatin analogue (letter). N Engl J Med 1985; 313:1229-1230.
12. Solcia E, Rindi G, Paolotti D, La Rosa S, Capella C, Fiocca R. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol 1999; 10(Suppl 2):S9-S15.
13. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-829.
14. Herder W, Lamberts SW. Gut endocrine tumours. Best Pract Res Clin Endocrinol Metab 2004; 18:477-495.
15. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10 (Suppl 2):S23-S29.
16. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. In: Lamberts SWJ, Dogliotti L, editors. The expanding role of octreotide I: advances in oncology. Bristol: Bioscentifica Ltd; 2002. pp. 17-30.
17. Oberg K. Carcinoid tumours, carcinoid syndrome and related disorders. In: Larsen R, Kronenberg H, Melmed S, Polonsky K, editors. Williams Textbook of Endocrinology. USA: Saunders; 2003. pp. 1857-1876.
18. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Digestion 1999; 60(Suppl 2):9-14.
19. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858-868.
20. Arnold R, Wied M, Behr T. Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract. Expert Opin Pharmacother 2002; 3:643-656.
21. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000; 12:368-377.
22. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10 (Suppl 2):S3-S8.
23. Kaltsas G, Papadogias D, Makras P, Grossman A. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12:683-699.
24. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62 (Suppl 1):92-97.
25. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351-1355.
26. Granberg D, Eriksson B, Wilander E, Grimfjard P, Fjallskog ML, Oberg K, Skogseid B. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12:1383-1391.
27. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, et al.; The Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006; 13:535-540.
28. Limouris GS, Dimitropoulos N, Kontogeorgakos D, Papanikolos G, Koutoulidis V, Hatzioannou A, et al. Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings. Cancer Biother Radiopharm 2005; 20:215-217.
29. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up J. Nucl Med 1994; 35:1637-1644.
30. McStay MK, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, Buscombe JR. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237:718-726.
31. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nuclear Med 2005; 46 (Suppl 1):62S-66S.
32. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10 (Suppl 2):S31-S38.
33. Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, et al. Sandostatin LAR (long acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17:437-444.
34. Eriksson B, Janson ET, Bax ND, Mignon M, Morant R, Opolon P, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumours. Digestion 1996; 57 (Suppl 1):77-80.
35. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004; 151:107-112.
36. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours A Consensus Statement on Behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80:394-424.
37. Siegbert F, Pape U-F, Böhmig M, Dörffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696.
38. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003; 10:463-468.